ASCO更新-肝细胞癌和胆管细胞癌

IF 0.4 Q4 ONCOLOGY

memo - Magazine of European Medical Oncology Pub Date : 2023-10-27 DOI:10.1007/s12254-023-00929-7

Angela Djanani

{"title":"ASCO更新-肝细胞癌和胆管细胞癌","authors":"Angela Djanani","doi":"10.1007/s12254-023-00929-7","DOIUrl":null,"url":null,"abstract":"Summary Two exciting phase 2 dates were presented at Asco. This results in a new phase III study for Hepatocelluar cancer that will be launched soon. With Cholangiocarcinoma there is a new substance that shows very good oberall response rates in a subgroup of patients.","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"6 1","pages":"0"},"PeriodicalIF":0.4000,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"ASCO update—hepatocellular carcinoma and cholangiocellular carcinoma\",\"authors\":\"Angela Djanani\",\"doi\":\"10.1007/s12254-023-00929-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Summary Two exciting phase 2 dates were presented at Asco. This results in a new phase III study for Hepatocelluar cancer that will be launched soon. With Cholangiocarcinoma there is a new substance that shows very good oberall response rates in a subgroup of patients.\",\"PeriodicalId\":18379,\"journal\":{\"name\":\"memo - Magazine of European Medical Oncology\",\"volume\":\"6 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2023-10-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"memo - Magazine of European Medical Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s12254-023-00929-7\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"memo - Magazine of European Medical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12254-023-00929-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

Asco上公布了两个激动人心的2期数据。这将导致一项新的肝细胞癌III期研究即将启动。对于胆管癌，有一种新的物质在一个亚组患者中显示出非常好的总体反应率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

ASCO update—hepatocellular carcinoma and cholangiocellular carcinoma

Summary Two exciting phase 2 dates were presented at Asco. This results in a new phase III study for Hepatocelluar cancer that will be launched soon. With Cholangiocarcinoma there is a new substance that shows very good oberall response rates in a subgroup of patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

memo - Magazine of European Medical Oncology ONCOLOGY-

CiteScore

1.80

自引率

16.70%

发文量

期刊介绍： memo is the Official Journal of the Central European Cooperative Oncology Group (CECOG) and The Austrian Society of Haematology and Oncology (OeGHO). The focus of the journal "magazine of european medical oncology – memo" is to offer a professional review on current research and development in the field of hematology and oncology relevant for daily practice. Therefore, memo includes editorials and comments, peer-reviewed original reports, short reviews, case reports and controversies, articles explaining the biology of neoplasia and congress reports including qualified comments. As a European journal memo aims at highlighting the local peculiarities of various regions and at being a forum for the presentation of ongoing clinical and basic research.